TG 6002

Drug Profile

TG 6002

Alternative Names: TG6002; VV-TK-RR-FCU1; VVWR-TK-RR--Fcu1

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Developer Assistance Publique Hopitaux de Paris; Transgene
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 26 Oct 2017 Phase-I/II clinical trials in Glioblastoma (Combination therapy, Second-line therapy or greater) in France (IV-infusion) (NCT03294486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top